LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, today provided a status update on the previously announced placement of its pre-commercial “LX Analyzer.” According to the update, the instrument LexaGene placed in a major U.S. hospital laboratory was configured to screen for COVID-19 and seven other respiratory pathogens. The company’s technology performs highly multiplex “RT-PCR,” which is a gold-standard chemistry that provides exceptional sensitivity and specificity. “These have been very exciting times for LexaGene where the device has been put into the field for testing of a novel pathogen,” Daryl Rebeck, LexaGene’s president and co-founder, stated in the news release. “Developing a tool for pandemic prevention is one of the main visions that Jack and I had when founding the company four years ago. The goal was always to provide testing that can be rapidly configured in an outbreak for early detection and containment, which we can accomplish with our open-access platform to help avoid delays and supply issues associated with all the closed access testing systems in the industry. As a foremost expert in biothreat and infectious diseases, Jack’s deep knowledge makes us very well suited to provide a solution to this ongoing pandemic that has created such a significant worldwide burden.”
To view the full press release, visit http://nnw.fm/E3AhN
About LexaGene Holdings Inc.
LexaGene is a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, enter sample ID and press “go.” The “LX Analyzer” delivers excellent sensitivity, specificity, and breadth of detection and can return results in about one hour. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest. For more information, visit the company’s website at www.LexaGene.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
